Genelux Corp (GNLX)

$2.46 -0.02 (-0.81%)
Market Cap 84.96M
Revenue (ttm) 170,000.00
Net Income (ttm) -28.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,647.06%
Debt to Equity Ratio 0.00
Volume 55,400
Avg Vol 136,002
Day's Range N/A - N/A
Shares Out 34.54M
Stochastic %K 41%
Beta -1.68
Analysts Strong Sell
Price Target $18.40

Latest News on GNLX

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Dec 13, 2024, 7:01 AM EST - 5 weeks ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 2 months ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 31, 2024, 10:59 AM EDT - 2 months ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 22, 2024, 4:01 PM EDT - 3 months ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:15 PM EDT - 3 months ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Sep 3, 2024, 4:01 PM EDT - 4 months ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Aug 14, 2024, 4:05 PM EDT - 5 months ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Jul 30, 2024, 7:00 AM EDT - 6 months ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 24, 2024, 8:00 AM EDT - 8 months ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 23, 2024, 4:01 PM EDT - 8 months ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

May 9, 2024, 4:25 PM EDT - 9 months ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 7:00 AM EDT - 10 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 27, 2023, 7:00 AM EST - 1 year ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Nov 14, 2023, 5:50 PM EST - 1 year ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 30, 2023, 1:56 PM EDT - 1 year ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Genelux Corporation Announces New Chief Financial Officer

Aug 28, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Aug 2, 2023, 4:00 PM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 20, 2023, 4:45 PM EDT - 1 year ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 11, 2023, 4:12 AM EDT - 1 year ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jul 10, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 29, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 22, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Genelux Corporation Announces $18 Million Private Placement

Jun 12, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Announces $18 Million Private Placement

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 25, 2023, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

Genelux Corporation Announces $33 Million Private Placement

May 15, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Announces $33 Million Private Placement

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 26, 2023, 10:50 PM EDT - 1 year ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Mar 23, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Genelux IPO prices at bottom of range

Jan 26, 2023, 6:40 AM EST - 2 years ago

Genelux IPO prices at bottom of range

Genelux Corporation Announces Pricing of Initial Public Offering

Jan 25, 2023, 9:00 PM EST - 2 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 1:49 PM EDT - 2 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Sep 19, 2022, 9:08 AM EDT - 2 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino